<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zahid MSH</submitter><funding>NIAID NIH HHS</funding><funding>National Institutes of Health</funding><pagination>fnab062</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8433491</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>368(11)</volume><pubmed_abstract>Host-directed therapies (HDTs) could enhance the activity of traditional antibiotics. AR-12 is a promising HDT against intracellular pathogens including Salmonella enterica serovar Typhimurium, and has been shown to act through modulation of autophagy and the Akt kinase pathway. Since AR-12 does not inhibit the growth of planktonic bacteria but only works in conjunction with the infected host-cell, we hypothesized that AR-12 could enhance the activity of antibiotics in less-susceptible strains in the intracellular host environment. We found that repetitive passaging of S. typhimurium in macrophages in the absence of antibiotics led to a 4-fold reduction in their intracellular susceptibility to streptomycin (STR), but had no effect on the bacteria's sensitivity to AR-12. Moreover, when the </pubmed_abstract><journal>FEMS microbiology letters</journal><pubmed_title>Overcoming reduced antibiotic susceptibility in intracellular Salmonella enterica serovar Typhimurium using AR-12.</pubmed_title><pmcid>PMC8433491</pmcid><funding_grant_id>R01AI125147</funding_grant_id><funding_grant_id>R01 AI125147</funding_grant_id><pubmed_authors>Ainslie KM</pubmed_authors><pubmed_authors>Johnson MM</pubmed_authors><pubmed_authors>Zahid MSH</pubmed_authors><pubmed_authors>Varma DM</pubmed_authors><pubmed_authors>Landavazo A</pubmed_authors><pubmed_authors>Bachelder EM</pubmed_authors><pubmed_authors>Blough BE</pubmed_authors></additional><is_claimable>false</is_claimable><name>Overcoming reduced antibiotic susceptibility in intracellular Salmonella enterica serovar Typhimurium using AR-12.</name><description>Host-directed therapies (HDTs) could enhance the activity of traditional antibiotics. AR-12 is a promising HDT against intracellular pathogens including Salmonella enterica serovar Typhimurium, and has been shown to act through modulation of autophagy and the Akt kinase pathway. Since AR-12 does not inhibit the growth of planktonic bacteria but only works in conjunction with the infected host-cell, we hypothesized that AR-12 could enhance the activity of antibiotics in less-susceptible strains in the intracellular host environment. We found that repetitive passaging of S. typhimurium in macrophages in the absence of antibiotics led to a 4-fold reduction in their intracellular susceptibility to streptomycin (STR), but had no effect on the bacteria's sensitivity to AR-12. Moreover, when the </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jun</publication><modification>2025-04-19T18:18:57.025Z</modification><creation>2025-04-19T18:18:57.025Z</creation></dates><accession>S-EPMC8433491</accession><cross_references><pubmed>34089315</pubmed><doi>10.1093/femsle/fnab062</doi></cross_references></HashMap>